Delian Capital

Founded in 2011, Delian Capital specializes in the field of tech-driven industry such as high-end manufacturing, cutting-edge technologies, and healthcare. Their investments range from robotics, Smart manufacturing Semiconductor, AI, big data, enterpriseservices, healthcare, etc. Examples of their investment portfolio: YueBoo、Hunan zhongli、 Esafenet、Venus MedTech、MicuRx、Rokae、 IMI、12 Sigma Technologies.

Fang Ph.D., Hong

Managing Director

48 past transactions

D2M Biotherapeutics

Series A in 2023
D2M Biotherapeutics focuses on the development of novel immunotherapeutics. The company is a tumor immunological drug developer that aims to expand the potential of immunotherapy.

Mech-Mind Robotics

Series C in 2022
Mech-Mind is a global leading provider of industrial 3D sensors and AI-powered software for intelligent robots, with 10,000+ cameras depoyed in 50+ countries and regions. By combining 3D vision with AI technology, Mech-Mind empowers partners and system integrators to manage challenging automation tasks, such as (de)palletizing, bin picking and assembly.

Zhongqu Technology

Series B in 2022
Zhongqu Technology is a 3D scanning technology company that focus on large space 3D digital research and development and Internet services. They provide digital empowerment for all industries with artificial intelligence technology.

AIForceTech

Series A in 2022
AIForceTech is a company that specializes in agricultural robotics. It is also accelerating the launch of new energy agricultural machinery, including unmanned pure electric tractors and a variety of electric-powered agricultural robot products. These products are currently being used in real-world scenarios and have gained valuable experience. AIForceTech was founded in 2019 and is headquartered in Beijing's Haidian District.

Hesguard

Seed Round in 2021
Hesguard is a medical device developer and producer of high-end implantable medical devices related to ophthalmic diseases.

Yuneng Technology

Series A in 2021
Yuneng Technology is an advanced materials developer of soft magnetic material used in battery and wireless efficient charging functions.

Yuntian Semiconductor

Series B in 2021
Yuntian Semiconductor is a semiconductor firm that develops TGV technology, filter wafer-level 3-D packaging technology, and IPD technology.

Lips Semiconductor

Series A in 2021
Lipps is a research and development, production and sales company of power semiconductor components. It can independently design IGBT/SIC, MOSFET modules and IPM module products, and has established a cooperative relationship with Japanese power module packaging factories.

Danwang Medical

Series A in 2021
Danwang Medical provides clinical transformation technology services to regenerative medicine for disease diagnosis and treatments. They also provide organoid drug sensitivity testing, organoid disease models, organoid drug development, and organoid chips. Danwang Medical is committed to applying the most recent clinical transformation technology of regenerative medicine to disease diagnosis and treatment, new drug screening, tumor marker development and identification, and other areas in order to provide clinical personalized treatment technology and accurate, efficient, and high-quality organoids Model to new drug research and development enterprises.

CalmCar Vision System

Series C in 2021
CalmCar Vehicle Vision is a Chinese intelligent driving vision system provider. They are specialized in developing intelligent vision system for ADAS, autopilot and autonomous driving with functions of Lane Departure Warning (LDW), Front Collision Warning (FCW), Pedestrian Collision Warning(PCW), Blind Spot Detection (BSD) and Traffic Sign Recognition (TSR).

xMEMS

Series A in 2021
xMEMS designs solutions and applications by integrating smart methodologies for a range of consumer electronics devices. The company was founded in 2018 and is headquartered in Santa Clara, California, United States.

Juventas

Series C in 2021
Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma.

AIForceTech

Series A in 2021
AIForceTech is a company that specializes in agricultural robotics. It is also accelerating the launch of new energy agricultural machinery, including unmanned pure electric tractors and a variety of electric-powered agricultural robot products. These products are currently being used in real-world scenarios and have gained valuable experience. AIForceTech was founded in 2019 and is headquartered in Beijing's Haidian District.

Hong Jing Drive

Series A in 2021
Hong Jing Drive is a full-stack autonomous driving solution provider. Automatic driving computing platform, selection and layout of sensors, full-stack software system integration, and calibration for automatic driving. Hong Jing Drive was established on May 2, 2018 by Feilong Liu in Hangzhou, Zhejiang.

ETHA Labs

Seed Round in 2021
ETHA Labs is a community-driven incubator for DeFi projects with the goal of lowering entry barriers for institutional and retail users in order to achieve mass adoption. Its ecosystem is divided into two parts: ETHA Lab (Build) focuses on developing critical infrastructure and tooling for DeFi, while ETHA Lab (Incubate) fosters new innovation and external DAO-based DeFi projects.

Zhishan Weixin Biotechnology

Series A in 2021
Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

Polaris Biology

Series B in 2020
Polaris Biology is a medical technology company specializing in the development and clinical application of cell-level precision diagnostic technology, is dedicated to exploring and studying individual and dynamic changes in tumors at the cellular level, and using this information to support clinical tumor diagnosis and treatment.

Sophonix

Series B in 2020
Sophonix focuses on the development, production and sales of in vitro diagnostic instruments and reagents, providing accurate POCT solutions.

YEESTOR

Series B in 2020
YEESTOR Microelectronics focuses on the developing and sales of storage controllers and manufactures of NAND Flash memory control chips. YEESTOR has been dedicated to continuous technical innovation, professional technical support and one-stop service for customers to achieve faster design cycles, higher resource utilization efficiency, and a more reliable storage system. YEESTOR closely follows the frontier of the market, compactly cooperates with module manufacturers and system manufacturers with overall arrangement, providing customers with complete turnkey solution and customized development platform. YEESTOR has mastered numerous key technologies in the industry, has various core invention patents at home and abroad, and has extensive global market operations experience. YEESTOR’s main product are storage controllers, including PCIe SSD Controller, SATA SSD Controller, UFS Controller, eMMC Controller, USB Controller, SD Controller and Security Storage Controller. Products are widely applied in data centers, servers, PCs, smart phones, tablet computers, smart homes, Internet of things, etc. YEESTOR was established in 2017 with headquarter in Shenzhen, branching in Hong Kong, Taiwan Hsinchu, Shanghai, Hefei and other places. YEESTOR was formed by the merger of SiliconGo (founded in 2007) and Auspitek (founded in 2015). YEESTOR is a significant global supplier of flash memory controller. Up to 2017, the cumulative shipments of YEESTOR and its predecessors reached 700 million units, which makes for a leader position in the industry.

Apexigen

Series C in 2020
Apexigen is a clinical-stage biopharmaceutical company developing antibody therapeutics for the treatment of cancer. It specializes in new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer.

Amunix

Series A in 2020
Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. By delivering breakthrough therapies that can safely harness the immune system, it aims to conquer cancer and save lives. Its pipeline products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform and have ongoing collaborations with biopharma corporations harnessing these delivery technologies over a wide range of therapeutic areas, delivering improved pharmaceutical technologies. Amunix was founded in 2006 and is headquartered in Mountain View, California.

Hummingbird Bioscience

Series B in 2019
Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.

SeekGene

Seed Round in 2019
SeekGene is a provider of genetic data analysis solutions focused on the development and clinical transformation of single cell sorting assays. The SeekGene operations team has many years of research and clinical service experience, focusing on the application of single-cell sequencing technology in real-world clinical research. Its self-developed high-throughput single-cell transcriptome sequencing kit achieves world-leading performance, and is flexible, simple, economical, and accurate, which can accelerate the clinical transformation of single-cell sequencing technology.

HiFiBiO

Series C in 2019
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

Lemon Photonics

Series A in 2019
LEMON Photonics Technologies Co. Ltd. is a high-tech company founded by a team of experienced laser professionals and venture capitals. LEMON focuses on research, sales and industrialization of high-end semiconductor electro-optical devices, modules and systems.

Rinfon

Series B in 2019
Rinfon is engaged in the research, development, production, sales and service of satellite and UAV communication products. It is the leading provider of satellite signal and module, system and solution for satellite and drone.

Knowbox

Series D in 2019
Established in 2014, Knowbox targets the K12 education field with two mobile apps currently helping students get the most from doing homework by providing personalized exercises. Teachers can use the mobile apps to better manage student homework by avoiding repetitive labor and securing more time to help each student's unique challenges. The company claims the two mobile apps currently have nearly one million daily active users, and plans to use the proceeds on building its own homework database.

Guofu Hydrogen

Series A in 2019
Furui Hydrogen was started by Furui Special Equipment Co. Ltd, a listed public company (stock 300338.sz) in China with market value of 3.8 billion RMB. Furui Special Equipment is a leader in LNG equipment market, and is credited with building up the LNG-transportation market in China. Furui Hydrogen aims to build up the hydrogen-for-mobility industry in China. Furui Hydrogen is a leader in the infrastructure equipment sector focused on heavy equipment for hydrogen fueling stations, on-vehicle hydrogen tanks and hydrogen liquefaction equipment. Furui Hydrogen targets three markets: Hydrogen filling station equipment, FCV hydrogen supply system and H2 liquifying system.

Panorama Medicine

Seed Round in 2019
Panorama Medicine is a developer of a drug discovery platform intended to offer data production and analysis through validation of discoveries. The company's platform integrates genomics and big data to develop therapeutic interventions, enabling medical companies to detect RNA defects in diseases. Panorama Medicine was founded in 2018 by Mingfu Zhu and is based in Bala Cynwyd, Pennsylvania, United States.

Archiwave Micro

Series A in 2019
Anqiwei Microelectronics was incorporated in July 2015 to focus on the development of high-performance RF microwave integrated circuits and module products based on silicon germanium SiGe BiCMOS, silicon-on-insulator SOI-CMOS and bulk silicon CMOS processes. Dr. Lu Jianhua, the founder of the company, received his Ph.D. from the University of California, Los Angeles (UCLA) and has been involved in RF and microwave integrated circuit design and product development in California. His products have won the ECN Impact Award. And Microwave Journal Best Product, and published the IEEE JSSC paper and several US patents as the first author. Several other core co-founders are top RF RF chip and system experts in the country and have accumulated decades of industry experience.

Recida Therapeutics

Series A in 2019
Recida Therapeutics is a Biotechnology company.

DFocus

Series A in 2018
As a global pioneer in smart space and smart building management, Shanghai DFocus Intelligent Technology Co., Ltd. is a leading technology company providing IoT services for real estate industry. With its headquarters in Shanghai and branch companies in Beijing and Shenzhen, DFocus provides services to over 200 large companies at home and abroad, including nearly 100 Fortune Global 500 companies, such as Microsoft, Huawei, China Merchants Bank, Alibaba, Porsche, Starbucks, and Budweiser. DFocus is also in strategic cooperation with renowned organizations and enterprises, such as Microsoft, Huawei, Tongji University Infrastructure Management Institute, BOMA, CoreNet, and Gensler, to establish and promote operation standards and practices for the industry.

Majorsec

Series A in 2018
Majorsec engages in enterprise-level endpoint security, providing users with operating system-based threat detection and protection. They offer security technologies such as EDR, CWPP, and adaptive micro-segmentation that improve users' ability to resist unknown threats, including ransomware, 0day vulnerabilities, APT attacks, and anti-kill Trojan horses, and enhance the ability to control the internal security status of hosts on the entire network.

BooCax

Series A in 2018
Beijing BooCax Technology Co., Ltd. is a supplier of core positioning and navigation technology for industrial mobile robot, as well as a supplier of robotic flexible collaboration system platform and AGV products.

DBSec

Series C in 2018
DBSec is a reputable supplier of data security products, services, and solutions. They provide database encryption systems, database audit systems, cloud data security products, and holistic data security solutions. They serve the government, finance, social security, energy, military, operator, education, medical, and other industries.

ABAX Sensing

Venture Round in 2018
ABAX is developing an ultra-low cost, small form factor automotive grade Lidar solution based on Frequency-Modulated Continuous Waves. The company is headquartered in Xian (CN).

OnKure Therapeutics

Series A in 2018
OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solid tumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies. OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.

EcoFlow Tech

Series A in 2018
EcoFlow is a revolutionary mobile power company that is reinventing the way the world accesses energy. As makers of industry-first, smart and powerful mobile power products, EcoFlow’s mission is to harness new technologies to foster inclusion and help raise standards of living in areas of the world where power shortages stunt economic growth and development.

Chance Pharmaceuticals

Series A in 2018
Chance Pharmaceuticals provides, discovers, develops, and commercializes inhalation therapies for the world’s debilitating diseases such as chronic obstructive pulmonary disease, asthma, pulmonary arterial hypertension, and central nervous system disorders.

MicuRx Pharmaceuticals

Series D in 2017
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.

12 Sigma Technologies

Series B in 2017
12 Sigma is an innovative healthcare company with leading artificial intelligence technology and medical imaging applications. They believe the combination of medical imaging and AI will have huge potential. It has formed partnerships with General Electric to jointly develop smart diagnosis products for tumor, cardiovascular disease and CT scan, as well as with 50 top-tier hospitals in China for applied medical diagnostics,technical research and clinical trials.

UniZ Technology

Series A in 2017
UniZ is a technology srartup that focuses on the development and distribution of affordable high performance 3D printing tools that help turn your dreams into reality. It is located in San Diego, CA, UniZ Technology LLC is a technology start-up co-founded by a group of engineers in Feb 2014.

Chance Pharmaceuticals

Angel Round in 2016
Chance Pharmaceuticals provides, discovers, develops, and commercializes inhalation therapies for the world’s debilitating diseases such as chronic obstructive pulmonary disease, asthma, pulmonary arterial hypertension, and central nervous system disorders.

Weizhi Keji

Series A in 2015
Weizhi Keji is a market information consultation and investigation industry.

51 Dinghuo

Series A in 2015
Fengyun Network offers industrial internet services in the communications, pan-maternal, and infant industries, providing integrated services of commodity supply chain, scenario financial solutions, and digital technology to the upstream and downstream customers of the industry.

HJIMI

Angel Round in 2015
HJIMI is a high-tech company that specializes in artificial intelligence with a focus on 3D computer vision, intelligent human-machine interaction, and 3D AR and MR technology. They serve retail, smart homes, consumer electronics, logistics, and other fields.

Nengdong Yingyu

Angel Round in 2014
Nengdong Yingyu is a learning and education platform. Active English has created a comprehensive set of scientific and rigorous curriculum systems to assist thousands of youngsters in learning English effortlessly and cheerfully. They provide services that include digital learning methods and products that include phonetic code, sentence rubik's cubes, and nine-nine syntax.

ZHZ

Venture Round in 2014
ZHZ is an industrial company that develops drones, helicopters and other products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.